Jan 11th - Women
in Clinical Trials.
Were you aware that for
20+ years – women of “child bearing potential” (meaning ages 12-60) were
specifically excluded from clinical trials?
How often have you seen results of studies reported out as male or
female results?
We have seen some of Caucasian
and African-American. What are your
thoughts? Do we need to know if women respond differently than men?
You Tube video on Women in Clinical Trails
You Tube video on Women in Clinical Trails
This comment has been removed by the author.
ReplyDeleteThis comment has been removed by the author.
DeleteI personally was unaware of the exclusion of women from clinical trials until we discussed it in pharmacy school. I think we tend to forget over time about the specifics of the data that has been gathered and just liberally apply the principles found from these older studies in practice today.
ReplyDeleteWith the big focus on evidence-based medicine, I think many studies and trials today often report the percent of male and female participants, but the conclusions are not often reported separately. We tend to lump results together to give a broad conclusion that can be applied in practice. Many articles that I researched in the past for various classes would state all the demographics in thorough detail of the description and results, but would be much broader in the abstract and focus on the conclusion of the trial, not the separate conclusions between the different subjects.
There is a need to know if women respond differently than men for some medications. For example, medicines to specifically treat prostate cancer would not necessarily need the results from women. I think future studies and trials should be designed with having both sexes in the participating population to truly get accurate data.
I was unaware until this class that women had been excluded from clinical trials for so long. I'm also surprised by the age range of women that is considered "child bearing potential". I think it is ridiculous that women were excluded just because they had the potential to become pregnant. The fact that women were still excluded even when pregnancy tests and various forms of contraception were available is what really confuses me. We had the potential to get even more data about a medication before it was available to the public and we didn't. I also find it interesting that we didn't want to study women in a controlled environment, but were willing to let them use the drug once it hit the market without knowing if it would affect them differently.
ReplyDeleteI also think it is strange that researchers thought that we could just assume that women would have the same response to medications as the men in the trials even though it is obvious that our bodies are vastly different. I believe that it is very important that we understand how women respond to medications differently than men. We had discussed in class that what works for a man may actually cause more harm to a similar female patient. That being said, if we use data from male only clinical trials and assume that it will also work for women, it may actually be more detrimental to the patient than it is helpful.
I had never really thought about it before, but I don't know that I have ever seen the results of a study reported out as male vs. female. Normally, they are reported as just one large sum without any indication of how many were women vs. men or if there were any women included at all, especially when looking at the results.
Like Megan and Jennie, I too was unaware of women being excluded from clinical trials in the recent past. I did not know that women of “child bearing potential” were specifically excluded although I had already done personal research regarding the thalidomide crisis. While researching clinical trials in pharmacy school, I have always looked at the size of trial groups but looking at gender was never something that was necessarily talked about. Something that interests me is that clinical trials done in specific areas like critical care or infectious disease have enough difficulty finding participants at all that perhaps it’s not deemed important, even today, to look at the sex of participants.
ReplyDeleteWe need to know if women respond differently than men, especially regarding cardiovascular (CV) health, since the number one cause of death for women is disease of the heart. In class, we looked at a chart about men versus women and CV disease (Bell et all: Pharmacotherapy 2000; 20:1034-1044); it showed rates of CV disease death has increased for women while decreasing for men in the 1990’s. Our class discussion linked this outcome to be most likely due to medication use since basically all clinical trials that dictated guideline-driven medicine were done in men alone post 1977. So not only is it unknown how to optimize medication use in women, but these medications and dosages that are beneficial in men may actually harm similar female patients. My point is that the gender disparity in studies like hypertension, heart failure, and aspirin use for CV disease prevention should be given top priority since cardiovascular health is linked to the highest female morbidity and mortality.
A question I still have about women in clinical trials is about Phase IV trials: is this data being reported by sex? If so, has this started to help fill in those knowledge gaps to fix the gender disparity in clinical trials done during the women of “child bearing potential” exclusion? If not, could Phase IV clinical trials be used in this way since they analyze a drug’s effect in various populations with long-term use?
As the others have mentioned, I too was unable of the exclusion of women from clinical trials for so long. It makes me wonder, what did they think of women? How much were they valued in society? Was our role to have a family (considered women were excluded of "child bearing potential")? To me, it appears this relates to gender equality in society.
ReplyDeleteIt is also interesting that women were not included in clinical trials because we are so different than men! We learn of the numerous ways men and women are different, so it seems natural that many drugs should also be tested in women. Trials should include women not only for safety, but to evaluate efficacy between men and women. One medication that may be the most efficacious of it's class among men may not be the same medication considered most efficacious among women for example. As I look at clinical trials in the future, I will be looking more closely at who was studied and if women were included.
In response to Kelsi's comment - I was thinking that they probably valued women due to the fact that they did not want to harm them, or their potential fetuses. However, some would say that it should be a decision a woman makes for herself rather than being told "no" by someone else. I don't know if they were trying to discredit a woman's potential use in the study, but I could see how it would come off that way.
ReplyDeleteOn a separate note, it seems like this is something that should be common sense. I don't know where the validity of using drugs in women would have come from had there been no women in clinical trials. If I were to be told to take a medication without having studies done in women, I would be hesitant to take the medication. So my question is, was it commonly known that women were not included in trials or were women mostly kept in the dark about that fact?
As so many have already said, I too was surprised to learn about the small amount of women that have historically been included in clinical trials. This was not something I had ever thought about until we began talking about it in both Kinetics and this class. Based on the information we have now and looking back clinical trials, it seems as though it would be common sense to include women in these trials in order to achieve complete data. And while I can somewhat understand the rationale in initially excluding women, especially when not much was known about these drugs and the times the studies took place, it still seems that excluding them from the trials even with certainty there was no pregnancy or possible harm to the fetus was a bit excessive, and women should have had more of a say in that. I think it is important that guidelines look to include information on how these drugs work in both women and men since we are so different, especially in terms of how our bodies handle the drugs. This would only help us in providing evidence based medicine to our patients and could be useful to many healthcare providers.
ReplyDeleteI was searching around online for information on the FDA involvement of women in clinical trials and found a strategic plan that they have been working on. It is called the Critical Path Initiative which essentially is working to develop tools including genetic markers, advanced imagining and using these biomarkers to predict any risks of side effects or responses to treatment in these trials. This technology will allow those involved in the research to understand the different responses that sub-populations have to medications, specifically the differences in response between men and women. Having this form of technology available will only improve our understanding of how these drugs will affect women and will allow them to be even better accounted for in these important drug trials. Our understanding for women’s health will be more of a focus in future trials and while some of these tools may be expensive for companies for development of a new drug, it would allow us to have a complete picture of these disease states and responses women have to drugs. All aspects of the research could be accounted for during the time of the trial and no questions would be left unanswered about how women may be affected when it comes to drug use in women.
http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM247231.pdf
This is an interesting article from 2007. Just highlight and then choose open in a new window. Everything with the FDA moves SLOWLY.
DeleteLike most people my generation and younger, I was unaware of the restrictions put on women in regards to clinical trials. I understand that they were just trying to protect women and seemed to be treating them with a lot of respect by not including them. But as forms of birth control became more available, I think this rule should have been lifted. Also, there should have been exceptions to this policy. It's hard to believe that they didn't see how important it was to have women in studies- a good reminder that the decisions we make today can affect people for many generations.
ReplyDelete
ReplyDeleteI was very unaware of the fact that clinical trials excluded women. And thinking back on the many studies that were given to us in class, I now realize that many never specified what gender was included in the study. I believe that we absolutely need to see how differently women respond than men. Women's bodies have very different hormones as well as body composition and I believe that this would make a big difference in how women respond in drug trials. From now on I will always pay close attention to who is included in trials and take that into account when using the information in them.
The extent to which women were disregarded in clinical trials truly amazes me. Furthermore, it is concerning that it does not seem to be common knowledge. I, personally, would feel hesitant to take medication prescribed to me if I knew women were excluded from the study. Women have distinct physiological differences from men and it is pertinent that we have data about how that affects drugs in the body; patient safety should be a priority.
ReplyDeleteI understand that pregnancy could be a worry among women of child-bearing age included in clinical trials, however, just because a woman is in the category of "child-bearing age," does not mean she will become pregnant in that time. Due to reproductive complications, abstinence, and a myriad of other possibilities, a woman may not be likely to become pregnant during the study even if she falls within that age range. Moreover, there are effective means of birth control, as well as early detection pregnancy tests available. It would be possible to take precautions to work with women in clinical trials. Women should not automatically be excluded from studies due to sex when the primary goal is to benefit both men and women. In health care, therapy is driven by evidence-based guidelines. Women should be equally included in clinical trials so that there is data to support practice.
It is important that the general public is aware of this inequality in health and safety. I speculate that if it were common knowledge, there may be a bigger push to get women included in clinical trials, overall improving women's health as a whole.
Like everyone has said, I was surprised to learn that women are commonly excluded from clinical trials. Even though sex-based equality has progressed in most other facets of our current society, it seems as if women are still excluded from these trials, even though chronic medical conditions arguably affect the female sex more so than the male sex. A study published by Marius Radenmaker in the American Journal of Clinical Dermatology also claims the female sex is twice as likely to suffer from adverse drug reactions.
ReplyDeleteWomen are proven to differ from men in lean body mass, hepatic clearance, and rate of drug metabolism. Drug companies must begin testing drugs in women to help prevent ADRs, as it has been also proven that drugs have been removed from the market after testing has concluded because of unacceptable side effects.
I was not aware of the strict exclusion of women in clinical trials. When reading studies, I notice that most of them include some demographics about the subjects. However, the results are not separated by sex. Rather, they are reported as a whole without regard to possible differences due to sex. Women may not only have different responses to medications then men, but the pathophysiology of the disease may also differ. It is important to have women in clinical trials with separate results to understand the best course of action for women. More recently, there has been a push to get women involved in more clinical trials to come up with more clinically relevant date specific to women. In 1994, the FDA established the Office of Women's Health with a twofold mission. It aims to protect and advance the health of women through policy, science and outreach, and to advocate for the participation of women in clinical trials and for sex, gender, and sub-population analysis. The group supports scientific research and collaboration with other government and national organizations to sponsor scientific and consumer outreach efforts. The organization has a research and development program to advance the evaluation of sex-based differences in the safety and efficacy of FDA-regulated products. They also track the participation of women and special populations in clinical studies and improve demographic subset analysis. This group has the potential to further the involvement of women in clinical studies to gain more information about how we can better treat women's health. This organization encourages women to participate in clinical studies and provides grants and special funding to those willing to study emerging and pressing women's health issues. I believe this organization could play a key role in advancing our knowledge of specifics about women 's health and response to drugs as long as it is made a priority.
ReplyDeleteI was unaware of the issue that women of childbearing age were not allowed to participate in clinical trials until it was said last year during kinetics. I believe that this is a serious problem that we have created in the health of the women today. For example, today we have all of these medications that that are used for high blood pressure that help prevent cardiovascular disease, yet women today are dying more frequently of cardiovascular disease compared to men because many of these clinical trials for these blood pressure medications were done using male participants. While we are all human beings, our bodies work differently and are different in regards to composition and shape. We have noticed this between races by the fact that certain races are poor metabolizes with certain enzymes and that certain races do not respond well to certain medications (African Americans with Ace inhibitors or ARBs).
ReplyDeleteI did a research project recently and saw that clinical trials for Xeljanz, an oral rheumatoid arthritis drug, contained a higher percentage of women than men in the studies. However, a majority of the people that get rheumatoid arthritis are women which would make sense to have more women in the study. At least for a disease state that tends to affect more women than men we are using women as participants in the study to see if the effects of the Xeljanz works for women.
In addition to many of my classmates, I was unaware of the exclusions and restrictions placed on women in regards to past clinical trials. Women were often excluded or underrepresented in clinical trials involving drug studies. Even though the data collected from the various trials is important in regards to the safety and efficacy of medications, a poor representation of demographics is displayed in these trials by only utilizing information from men. Women and men have extremely different profiles, in which medications are absorbed, distributed, metabolized, and excreted in the human body. Knowing that the clinical trials only include information from men makes me hesitant to rely on the safety and efficacy profiles, especially when dispensing medications to women. As a woman and healthcare professional, I aspire to provide the most effective and passionate care I can to myself, family members, and patients.
ReplyDeleteUntil this class, I was unaware that women of “child bearing potential” had been excluded from clinical trials for such a long period of time. Especially since women make up a large percentage of the population that uses medications, I think that it was wrong for women to be excluded. Additionally, women are very different from men based upon basic physiologic makeup. Therefore, medications should be tested in women to ensure safety and efficacy for women. In the past, I had not really noticed if the results of studies had reported out as male or female results. In the future, however, I plan to pay much closer attention to this aspect in order to make the best recommendations for my female patients.
ReplyDelete